natgillin/translations-raw huggingface dataset:
If you have taken too many tablets of Exforge, or if someone else has taken your tablets, consult a doctor immediately. 
Če ste vzeli večji odmerek zdravila Exforge, kot bi smeli Če ste vzeli preveč tablet zdravila Exforge, ali je vaše tablete vzel kdo drug, se takoj posvetujte z zdravnikom.
No drug-drug interaction studies have been performed with Exforge and other medicinal products. 
Študij medsebojnega delovanja z zdravilom Exforge in drugimi zdravili niso izvedli.
• Concomitant use of Exforge with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see sections 4.5 and 5.1). 
• Sočasna uporaba zdravila Exforge in zdravil, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo ali z okvaro ledvic (GFR <60 ml/min/1,73m2) (glejte poglavji 4.5 in 5.1).
Other possible side effects of Exforge: 
Drugi možni neželeni učinki zdravila Exforge:
If a diurectic is also used, the risk of lithium toxicity may presumably be increased further with Exforge. 
Če je uporabljen tudi diuretik, uporaba zdravila Exforge predvidoma poveča toksične učinke litija.
Exforge is available in packs containing 7, 14, 28, 30, 56, 90, 98 or 280 tablets and in multipacks comprising 4 cartons, each containing 70 tablets, or 20 cartons, each containing 14 tablets. 
Zdravilo Exforge je na voljo v pakiranjih, ki vsebujejo 7, 14, 28, 30, 56, 90, 98 ali 280 tablet in v skupnih pakiranjih s 4 škatlami, od katerih vsaka vsebuje 70 tablet, ali z 20 škatlami, od katerih vsaka vsebuje 14 tablet.
Exforge was also studied in an active-controlled study of 130 hypertensive patients with mean sitting diastolic blood pressure ≥110 mmHg and <120 mmHg. 
Zdravilo Exforge so raziskali tudi v študiji, kontrolirani z učinkovino, pri 130 bolnikih s hipertenzijo, ki so imeli srednji diastolični krvni tlak sede ≥110 mm Hg in <120 mm Hg.
Exforge has not been studied in any patient population other than hypertension. 
Zdravilo Exforge ni raziskano pri nobeni drugi populaciji razen pri bolnikih s hipertenzijo.
The amlodipine component of Exforge inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle. 
Amlodipin v zdravilu Exforge zavira transmembranski vstop kalcijevih ionov v srčne in žilne gladke mišice.
If you get these symptoms, stop taking Exforge and contact your doctor straight away. 
Če opazite navedene simptome, takoj prenehajte jemati zdravilo Exforge in obvestite svojega zdravnika.
Exforge combines two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines. 
Zdravilo Exforge vsebuje dve antihipertenzivni učinkovini s komplementarnima mehanizmoma delovanja za obvladanje krvnega tlaka pri bolnikih z esencialno hipertenzijo: amlodipin spada med zaviralce kalcijevih kanalčkov, valsartan pa med antagoniste angiotenzina II.
Frequency Exforge Amlodipine Valsartan 
Pogostnost Exforge Amlodipin Valsartan
Do not take Exforge with grapefruit or grapefruit juice. 
Zdravila Exforge ne zaužijte skupaj z grenivko ali z grenivkinim sokom.
The rate and extent of absorption of Exforge are equivalent to the bioavailability of valsartan and amlodipine when administered as individual tablets. 
Hitrost in obseg absorpcije zdravila Exforge sta enakovredna biološki uporabnosti valsartana in amlodipina, uporabljenih v ločenih tabletah.
If you forget to take Exforge 
Če ste pozabili vzeti zdravilo Exforge
If hypotension occurs with Exforge, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. 
Če se med uporabo zdravila Exforge pojavi hipotenzija, je treba bolnika poleči in mu, če je potrebno, dati intravensko infuzijo fiziološke raztopine.
Correction of this condition prior to administration of Exforge or close medical supervision at the start of treatment is recommended. 
Priporočljivo je, da pred začetkom uporabe zdravila Exforge, popravite to stanje ali bolniku zagotovite natančen zdravniški nadzor na začetku zdravljenja.
Clinically significant hypotension due to Exforge overdose calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. 
Klinično značilna hipotenzija zaradi prevelikega odmerka zdravila Exforge zahteva srčnožilno podporo, vključno s pogostim nadziranjem delovanja srca in dihal, dviganjem udov ter kontrolo krožečega volumna tekočine in izločanja urina.
What Exforge is and what it is used for What you need to know before you take Exforge How to take Exforge 
Kaj je zdravilo Exforge in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Exforge Kako jemati zdravilo Exforge Možni neželeni učinki
Exforge is not recommended for mothers who are breastfeeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely. 
Če želite dojiti, bo zdravnik za vas izbral drugo zdravilo, še posebno če je vaš otrok še novorojenček ali je bil rojen prezgodaj.
Exforge can be used with or without food. 
Zdravilo Exforge lahko vzamete s hrano ali brez nje.
Particular caution should be exercised when administering Exforge to patients with mild to moderate hepatic impairment or biliary obstructive disorders. 
Posebna previdnost je potrebna v primeru uporabe zdravila Exforge pri bolnikih z blago do zmerno okvaro jeter ali z obstruktivnimi biliarnimi boleznimi.
Adverse reactions previously reported with one of the individual components (amlodipine or valsartan) may be potential adverse reactions with Exforge as well, even if not observed in clinical trials or during the post-marketing period. 
Dodatne informacije o posameznih zdravilnih učinkovinah Neželeni učinki, opisani za katero od obeh zdravilnih učinkovin (za amlodipin ali valsartan), so lahko tudi neželeni učinki zdravila Exforge, tudi če niso bili ugotovljeni v kliničnih preskušanjih ali v obdobju po prihodu zdravila na trg.
This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Exforge. 
Grenivka in grenivkin sok lahko namreč povzročita zvišanje koncentracije zdravilne učinkovine amlodipina v krvi, kar lahko pripelje do nepredvidljivega povečanja učinka zdravila Exforge pri zniževanju krvnega tlaka.
If you stop taking Exforge 
Če ste prenehali jemati zdravilo Exforge
In this study (baseline blood pressure 171/113 mmHg), an Exforge regimen of 5 mg/160 mg titrated to 10 mg/160 mg reduced sitting blood pressure by 36/29 mmHg as compared to 32/28 mmHg with a regimen of lisinopril/hydrochlorothiazide 10 mg/12.5 mg titrated to 20 mg/12.5 mg. 
V tej študiji (izhodiščni krvni tlak 171/113 mm Hg) je shema odmerjanja zdravila Exforge 5 mg/160 mg, titrirana do 10 mg/160 mg, znižala krvni tlak sede za 36/29 mm Hg; v primerjavi s tem je shema odmerjanja lizinoprila/hidroklorotiazida 10 mg/12,5 mg, titrirana do 20 mg/12,5 mg, znižala krvni tlak za 32/28 mm Hg.
Caution should be exercised when administering Exforge to patients with hepatic impairment or biliary obstructive disorders (see section 4.4). 
Previdnost je potrebna pri uporabi zdravila Exforge pri bolnikih z okvaro jeter ali obstruktivno biliarno boleznijo (glejte poglavje 4.4).
If any of these apply to you, tell your doctor before taking Exforge. 
Če kaj od naštetega velja za vas, morate to povedati zdravniku, preden vzamete zdravilo Exforge.
How to take Exforge 
Kako jemati zdravilo Exforge
Side effects reported with amlodipine or valsartan alone and either not observed with Exforge or observed with a higher frequency than with Exforge: 
Neželeni učinki, o katerih so poročali pri uporabi amlodipina ali valsartana samega, ki jih bodisi niso opažali pri uporabi zdravila Exforge ali pa so jih opažali z večjo pogostnostjo kot pri uporabi zdravila Exforge:
Excessive hypotension was seen in 0.4% of patients with uncomplicated hypertension treated with Exforge in placebo-controlled studies. 
V študijah, kontroliranih s placebom, so čezmerno hipotenzijo opažali pri 0,4 % bolnikov z nezapleteno hipertenzijo, ki so dobivali zdravilo Exforge.
Following oral administration of Exforge, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6-8 hours, respectively. 
Po peroralni uporabi zdravila Exforge doseže valsartan največjo koncentracijo v plazmi v 3 urah, amlodipin pa v 6 do 8 urah.
Exforge tablets contain two substances called amlodipine and valsartan. 
Tablete zdravila Exforge vsebujejo dve učinkovini: amlodipin in valsartan.
Over 1,400 hypertensive patients received Exforge once daily in two placebo-controlled trials. 
V dveh s placebom kontroliranih preskušanjih je zdravilo Exforge enkrat na dan dobivalo več kot 1.400 bolnikov s hipertenzijo.
When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to amlodipine or Exforge, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used. 
Pri prehodu ustreznih bolnikov s hipertezijo (glejte poglavje 4.1) z jetrno okvaro na amlodipin ali zdravilo Exforge, je potrebno uporabiti najnižji razpoložljivi odmerek amlodipina v monoterapiji ali kot komponento.
Exforge is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy. 
Zdravilo Exforge je indicirano pri odraslih, pri katerih krvni tlak ni ustrezno urejen ob monoterapiji z amlodipinom ali valsartanom.
Exforge is used to treat high blood pressure in adults whose blood pressure is not controlled enough with either amlodipine or valsartan on its own. 
Zdravilo Exforge uporabljamo za zdravljenje visokega krvnega tlaka pri odraslih, pri katerih krvni tlak ni dovolj dobro urejen samo z amlodipinom ali samo z valsartanom.
ACE inhibitors or aliskiren (see also information under the headings “Do not take Exforge” and “Warnings and precautions”); diuretics (a type of medicine also called “water tablets” which increases the amount of urine you produce); lithium (a medicine used to treat some types of depression); potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels; certain types of painkillers called non-steroidal anti-inflammatory medicines (NSAIDs) or selective cyclooxygenase-2 inhibitors (COX-2 inhibitors). 
To še posebej velja za naslednja zdravila: zaviralci ACE ali aliskiren (glejte tudi informacije pod naslovoma “Ne jemljite zdravila Exforge” in “Opozorila in previdnostni ukrepi”); diuretike (vrsto zdravil, ki jim pravimo tudi "tablete za odvajanje vode" in povečajo nastajanje urina v telesu); litij (zdravilo, ki se uporablja za zdravljenje nekaterih vrst depresij); diuretike, ki varčujejo s kalijem, kalijeve dodatke, nadomestke soli, ki vsebujejo kalij, in druge učinkovine, ki lahko zvišajo koncentracijo kalija; določena zdravila proti bolečinam, ki jih imenujemo nesteroidna protivnetna zdravila (NSAID) ali selektivni zaviralci ciklooksigenaze-2 (zaviralci COX-2).
Talk to your doctor before taking Exforge: if you have been sick (vomiting or diarrhoea). 
Opozorila in previdnostni ukrepi Pred začetkom jemanja zdravila Exforge se posvetujte z zdravnikom: če vam je bilo slabo (bruhanje ali driska).
There are no clinical studies on fertility with Exforge. 
Kliničnih študij glede plodnosti pri uporabi zdravila Exforge ni.
When switching eligible elderly hypertensive patients (see section 4.1) to amlodipine or Exforge, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used. 
Pri prehodu ustreznih starejših bolnikov s hipertezijo (glejte poglavje 4.1) na amlodipin ali zdravilo Exforge, je potrebno uporabiti najnižji razpoložljivi odmerek amlodipina v monoterapiji ali kot komponento.
Exforge should be used with caution to treat hypertension in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney since blood urea and serum creatinine may increase in such patients. 
Pri bolnikih z enostransko ali obojestransko stenozo ledvične arterije oz. s stenozo v primeru solitarne ledvice je pri zdravljenju hipertenzije z zdravilom Exforge potrebna previdnost, saj pri takih bolnikih lahko pride do zvišanja koncentracij sečnine v krvi in kreatinina v serumu.
The active substances of Exforge are amlodipine (as amlodipine besylate) and valsartan. 
Učinkovini v zdravilu Exforge sta amlodipin (v obliki amlodipinijevega besilata) in valsartan.
Hepatic impairment Exforge is contraindicated in patients with severe hepatic impairment (see section 4.3). 
Okvara jeter Pri bolnikih s hudo okvaro jeter je zdravilo Exforge kontraindicirano (glejte poglavje 4.3).
There is no experience of overdose with Exforge. 
Izkušenj s prevelikim odmerjanjem zdravila Exforge ni.
No information is available regarding the use of Exforge during breast-feeding, therefore Exforge is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant. 
Za uporabo med dojenjem je bolje izbrati drugo zdravilo z dokazanim varnostnim profilom, še posebno če gre za dojenje novorojenčka ali nedonošenčka.
Do not use any Exforge pack that is damaged or shows signs of tampering. 
Zdravila Exforge ne uporabljajte, če je ovojnina poškodovana ali opazite, da je bila že odprta.
Rare (may affect up to 1 in 1,000 people): Feeling anxious; ringing in the ears (tinnitus); fainting; passing more urine than normal or feeling more of an urge to pass urine; inability to get or maintain an erection; sensation of heaviness; low blood pressure with symptoms such as dizziness, light headedness; excessive sweating; skin rash all over your body; itching; muscle spasm.If any of these affect you severely, tell your doctor. 
Redki (pojavijo se pri do 1 od 1.000 ljudi): občutek tesnobe; zvonjenje v ušesih (tinitus); omedlevica; izločanje več urina kot ponavadi ali pogostejše siljenje na vodo; nezmožnost za doseganje ali ohranitev erekcije; občutek teže; nizek krvni tlak s simptomi, kot sta omotica in vrtoglavost; čezmerno znojenje; osip po koži po vsem telesu; srbenje; mišični krči.
If any of the above applies to you, do not take Exforge and talk to your doctor. 
Če kaj od naštetega velja za vas, ne vzemite zdravila Exforge, temveč povejte zdravniku.
Exforge 5 mg/80 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg alone. 
Zdravilo Exforge 5 mg/80 mg lahko uporabite pri bolnikih, pri katerih krvni tlak ni ustrezno urejen samo s 5 mg amlodipina ali z 80 mg valsartana.
No dosage adjustment of Exforge is required for patients with mild to moderate renal impairment (GFR >30 ml/min/1.73 m2). 
Pri bolnikih z blago do zmerno okvaro ledvic (GFR >30 ml/min/1,73 m2) odmerka zdravila Exforge ni treba prilagajati.
Exforge 10 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg alone or with Exforge 5 mg/160 mg. 
Zdravilo Exforge 10 mg/160 mg lahko uporabite pri bolnikih, pri katerih krvni tlak ni ustrezno urejen samo z 10 mg amlodipina ali s 160 mg valsartana ali s kombinacijo zdravila Exforge 5 mg/160 mg.
What Exforge contains 
Kaj vsebuje navodilo
Exforge 10 mg/160 mg tablets are oval and light yellow with “NVR” on one side and “UIC” on the other side. 
Tablete zdravila Exforge 10 mg/160 mg so ovalne in svetlorumene; na eni strani imajo oznako “NVR” in na drugi “UIC”.
Exforge 5 mg/80 mg film-coated tablets Exforge 5 mg/160 mg film-coated tablets Exforge 10 mg/160 mg film-coated tablets 
Exforge 5 mg/80 mg filmsko obložene tablete Exforge 5 mg/160 mg filmsko obložene tablete Exforge 10 mg/160 mg filmsko obložene tablete
Exforge 5 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg alone. 
Zdravilo Exforge 5 mg/160 mg lahko uporabite pri bolnikih, pri katerih krvni tlak ni ustrezno urejen samo s 5 mg amlodipina ali 160 mg valsartana.
Exforge 5 mg/80 mg film-coated tablets 
Exforge 5 mg/80 mg filmsko obložene tablete
Exforge 5 mg/160 mg tablets are oval and dark yellow “NVR” on one side and “ECE” on the other side. 
Tablete zdravila Exforge 5 mg/160 mg so ovalne in temnorumene; na eni strani imajo oznako “NVR” in na drugi “ECE”.
Exforge 10 mg/160 mg film-coated tablets 
Exforge 10 mg/160 mg filmsko obložene tablete
Grapefruit and grapefruit juice should not be consumed by people who are taking Exforge. 
Ljudje, ki jemljejo zdravilo Exforge, ne smejo uživati grenivk in grenivkinega soka.
Exforge 5 mg/80 mg film-coated tablets Exforge 5 mg/160 mg film-coated tablets Exforge 10 mg/160 mg film-coated tablets amlodipine/valsartan 
Exforge 5 mg/80 mg filmsko obložene tablete Exforge 5 mg/160 mg filmsko obložene tablete Exforge 10 mg/160 mg filmsko obložene tablete amlodipin/valsartan
Hypromellose, substitution type 2910 (3 mPa.s) Titanium dioxide (E171) Iron oxide, yellow (E172) Macrogol 4000 
Hipromeloza, substitucijski tip 2910 (3 mPa.s) titanov dioksid (E171) rumeni železov oksid (E172) makrogol 4000 smukec
Exforge 10 mg/160 mg film-coated tablets amlodipine/valsartan 
Exforge 10 mg/160 mg filmsko obložene tablete amlodipin/valsartan
Exforge should be discontinued immediately in patients who develop angioedema and should not be re-administered. 
Bolnikom, pri katerih pride do angioedema, je treba zdravilo Exforge takoj ukiniti.
Exforge 5 mg/160 mg film-coated tablets 
Exforge 5 mg/160 mg filmsko obložene tablete
EU/1/06/370/035 280 film-coated tablets (4x70) EU/1/06/370/038 280 film-coated tablets (20x14) 
EU/1/06/370/035 280 filmsko obloženih tablet (4x70) EU/1/06/370/038 280 filmsko obloženih tablet (20x14)
What Exforge looks like and contents of the pack Exforge 5 mg/80 mg tablets are round and dark yellow with “NVR” on one side and “NV” on the other side. 
Tablete zdravila Exforge 5 mg/80 mg so okrogle in temnorumene; na eni strani imajo oznako “NVR” in na drugi “NV”.
EU/1/06/370/036 280 film-coated tablets (4x70) EU/1/06/370/039 280 film-coated tablets (20x14) 
EU/1/06/370/036 280 filmsko obloženih tablet (4x70) EU/1/06/370/039 280 filmsko obloženih tablet (20x14)
EU/1/06/370/034 280 film-coated tablets (4x70) EU/1/06/370/037 280 film-coated tablets (20x14) 
EU/1/06/370/034 280 filmsko obloženih tablet (4x70) EU/1/06/370/037 280 filmsko obloženih tablet (20x14)
Exforge 5 mg/80 mg film-coated tablets amlodipine/valsartan 
Exforge 5 mg/80 mg filmsko obložene tablete amlodipin/valsartan
How to store Exforge 
Shranjevanje zdravila Exforge
Exforge 5 mg/160 mg film-coated tablets amlodipine/valsartan 
Exforge 5 mg/160 mg filmsko obložene tablete amlodipin/valsartan
* Mostly consistent with cholestasis 
* o tem so najpogosteje poročali v povezavi s holestazo Dodatne informacije o kombinaciji
EU/1/06/370/001 7 film-coated tablets EU/1/06/370/002 14 film-coated tablets EU/1/06/370/003 28 film-coated tablets EU/1/06/370/004 30 film-coated tablets EU/1/06/370/005 56 film-coated tablets EU/1/06/370/006 90 film-coated tablets EU/1/06/370/007 98 film-coated tablets EU/1/06/370/008 280 film-coated tablets EU/1/06/370/025 56x1 film-coated tablet (unit dose) EU/1/06/370/026 98x1 film-coated tablet (unit dose) EU/1/06/370/027 280x1 film-coated tablet (unit dose) 
EU/1/06/370/001 7 filmsko obloženih tablet EU/1/06/370/002 14 filmsko obloženih tablet EU/1/06/370/003 28 filmsko obloženih tablet EU/1/06/370/004 30 filmsko obloženih tablet EU/1/06/370/005 56 filmsko obloženih tablet EU/1/06/370/006 90 filmsko obloženih tablet EU/1/06/370/007 98 filmsko obloženih tablet EU/1/06/370/008 280 filmsko obloženih tablet EU/1/06/370/025 56x1 filmsko obložena tableta (za enkratni odmerek) EU/1/06/370/026 98x1 filmsko obložena tableta (za enkratni odmerek) EU/1/06/370/027 280x1 filmsko obložena tableta (za enkratni odmerek)
Myalgia 
Obloga
EU/1/06/370/017 7 film-coated tablets EU/1/06/370/018 14 film-coated tablets EU/1/06/370/019 28 film-coated tablets EU/1/06/370/020 30 film-coated tablets EU/1/06/370/021 56 film-coated tablets EU/1/06/370/022 90 film-coated tablets EU/1/06/370/023 98 film-coated tablets EU/1/06/370/024 280 film-coated tablets EU/1/06/370/031 56x1 film-coated tablet (unit dose) EU/1/06/370/032 98x1 film-coated tablet (unit dose) EU/1/06/370/033 280x1 film-coated tablet (unit dose) 
EU/1/06/370/017 7 filmsko obloženih tablet EU/1/06/370/018 14 filmsko obloženih tablet EU/1/06/370/019 28 filmsko obloženih tablet EU/1/06/370/020 30 filmsko obloženih tablet EU/1/06/370/021 56 filmsko obloženih tablet EU/1/06/370/022 90 filmsko obloženih tablet EU/1/06/370/023 98 filmsko obloženih tablet EU/1/06/370/024 280 filmsko obloženih tablet EU/1/06/370/031 56x1 filmsko obložena tableta (za enkratni odmerek) EU/1/06/370/032 98x1 filmsko obložena tableta (za enkratni odmerek) EU/1/06/370/033 280x1 filmsko obložena tableta (za enkratni odmerek)
EU/1/06/370/009 7 film-coated tablets EU/1/06/370/010 14 film-coated tablets EU/1/06/370/011 28 film-coated tablets EU/1/06/370/012 30 film-coated tablets EU/1/06/370/013 56 film-coated tablets EU/1/06/370/014 90 film-coated tablets EU/1/06/370/015 98 film-coated tablets EU/1/06/370/016 280 film-coated tablets EU/1/06/370/028 56x1 film-coated tablet (unit dose) EU/1/06/370/029 98x1 film-coated tablet (unit dose) EU/1/06/370/030 280x1 film-coated tablet (unit dose) 
EU/1/06/370/009 7 filmsko obloženih tablet EU/1/06/370/010 14 filmsko obloženih tablet EU/1/06/370/011 28 filmsko obloženih tablet EU/1/06/370/012 30 filmsko obloženih tablet EU/1/06/370/013 56 filmsko obloženih tablet EU/1/06/370/014 90 filmsko obloženih tablet EU/1/06/370/015 98 filmsko obloženih tablet EU/1/06/370/016 280 filmsko obloženih tablet EU/1/06/370/028 56x1 filmsko obložena tableta (za enkratni odmerek) EU/1/06/370/029 98x1 filmsko obložena tableta (za enkratni odmerek) EU/1/06/370/030 280x1 filmsko obložena tableta (za enkratni odmerek)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
Izgled zdravila Exforge in vsebina pakiranja
If any of the following happen, tell your doctor straight away: 
Če se karkoli od naštetega pri vas pojavi v hudi obliki, morate to povedati zdravniku.
This summary was last updated in 02-2012. 
Povzetek je bil nazadnje posodobljen 01-2016.
The full EPAR for Clopidogrel Acino can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Klopidogrel Acino je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
• patients who have recently had a myocardial infarction (heart attack). 
• ki so nedavno doživeli miokardni infarkt (srčni napad).
For more information about treatment with Clopidogrel Acino, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Klopidogrel Acino preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
This is a summary of the European public assessment report (EPAR) for Clopidogrel Acino. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Klopidogrel Acino.
This means that Clopidogrel Acino is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Plavix.
• patients with peripheral arterial disease (problems with blood flow in the arteries); 
• ki imajo periferno arterijsko bolezen (težave s pretokom krvi v arterijah);
The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel Acino on 28 July 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Klopidogrel Acino, veljavno po vsej Evropski uniji, izdala 28. julija 2009.